Ambeed.cn

首页 / / / / Pembrolizumab/帕博利珠单抗

Pembrolizumab/帕博利珠单抗 {[allProObj[0].p_purity_real_show]}

货号:A1174800 同义名: MK-3475; Lambrolizumab

Pembrolizumab是一种人源化IgG4单克隆抗体,通过与PD-1受体结合来阻止其与配体结合。Pembrolizumab具有用于多种癌症(如黑色素瘤、非小细胞肺癌)研究的潜力。

HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Pembrolizumab/帕博利珠单抗 化学结构 CAS号:1374853-91-4
Pembrolizumab/帕博利珠单抗 化学结构
CAS号:1374853-91-4
Pembrolizumab/帕博利珠单抗 3D分子结构
CAS号:1374853-91-4
Pembrolizumab/帕博利珠单抗 化学结构 CAS号:1374853-91-4
Pembrolizumab/帕博利珠单抗 3D分子结构 CAS号:1374853-91-4
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePriceInt(item.pr_rmb, 1,1) ]}

{[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}

{[ getRatePriceInt(item.pr_rmb, 1,1) ]}

{[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} 现货 1周 咨询 - +
购物车0 收藏 询单

Pembrolizumab/帕博利珠单抗 纯度/质量文件 产品仅供科研

货号:A1174800 标准纯度: {[allProObj[0].p_purity_real_show]}
批次查询: 批次纯度:

全球学术期刊中引用的产品

Nature, 2025, 645, 793-800. Ambeed. [ A201204 , A444152 , A344107 , A952055 ]
Cell, 2025. Ambeed. [ A122167 ]
Science, 2025, 387(6729): eadp5637. Ambeed. [ A875019 ]
Sig. Transduct. Target. Ther., 2025, 10, 257. Ambeed. [ A104916 ]
Nat. Nanotechnol., 2025. Ambeed. [ A243018 , A1216705 , A522597 , A125401 , A1355641 ]
更多 >
产品名称 PD-1 PD-1/PD-L1 PD-1/PD-L1 interaction PD-L1 其他靶点 纯度
SR0987 99%
Pembrolizumab 98%
Camrelizumab 95%
Spartalizumab 95%
BMS-1001 +

PD-1/PD-L1, EC50: 253 nM

+

PD-1/PD-L1, EC50: 253 nM

98%
INCB086550 ++

PD-1/PD-L1, IC50: <10 nM

++

PD-1/PD-L1, IC50: <10 nM

98%
BMS-1 ++

PD-1/PD-L1 interaction, IC50: 0.006 μM

99%+
BMS-202 +

PD-1/PD-L1 interaction, IC50: 0.018 μM

99%+
PD-1/PD-L1-IN 3 +++

PD-1/PD-L1 interaction, IC50: 5.6 nM

98+%
Nivolumab +++

PD-1/PD-L1 interaction, IC50: 2.52 nM

95%
BMS-1166 +++

PD-1/PD-L1 interaction, IC50: 1.4 nM

99%+
Durvalumab ++++

PD-1/PD-L1 interaction, IC50: 0.1 nM

95%
Evixapodlin ++++

PD-1/PD-L1, IC50: 0.213 nM

95%
CA-170 97% (contains 2.7% ethanol)
Atezolizumab +++

hPD-L1, Kd: 0.4 nM

99%
AUNP-12 98%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。

Pembrolizumab/帕博利珠单抗 生物活性

靶点
  • PD-1

描述

Product Name: Pembrolizumab

Cross-reactivity: Human,Cynomolgus

Organism:Human

Target name: PDCD1 / PD-1 / CD279

Recommended Dilution Buffer: Sterile PBS or 0.9% saline for reconstitution/dilution. It is recommended to use the reconstituted/diluted product within one month.

Formulation: 100 mM Pro-Ac,20 mM Arg,pH5.0

Endotoxin: < 0.001EU/μg, determined by LAL method.

Purity: >95%. Determined by SDS-PAGE

Purification: Purified, Protein A, affinity column

Storage: -80°C for 2 years under sterile conditions; -20°C for 1 year under sterile conditions; Avoid repeated freeze-thaw cycles.

Isotype: IgG4SP-Kappa

Pembrolizumab/帕博利珠单抗 细胞实验

Cell Line
Concentration Treated Time Description References
SFMCs (21-day culture) 5 μg/mL 21 days To investigate the effect of Pembrolizumab on TRAP secretion in SFMCs, results showed Pembrolizumab did not significantly increase TRAP secretion (P = 0.28). Arthritis Res Ther. 2022 Feb 14;24(1):43
Human EA.hy926 endothelial cells 100 μg/ml 24 hours Study the toxic effect of Pembrolizumab on endothelial cells, finding that atorvastatin could prevent this toxicity Basic Res Cardiol. 2025 Feb;120(1):263-286
Splenocytes 0-100 μg/ml 24 hours Assess the effect of ICIs on immune cells, finding that Pembrolizumab at high doses induced increased Th17-type cytokine expression Basic Res Cardiol. 2025 Feb;120(1):263-286
Human spermatozoa 1-100 ng/mL 4 hours To evaluate the effect of Pembrolizumab on human sperm motility. Results showed that Pembrolizumab significantly reduced sperm motility at concentrations of 10 ng/mL and above. Front Pharmacol. 2025 Mar 31;16:1534975
PBMCs 5 µg/mL pembroliz µMab and 1 µg/mL rhGal-3 48 hours Investigate the effect of Gal-3 and pembrolizumab on IL-2 production, results showed Gal-3 significantly decreased IL-2 production and pembrolizumab could not rescue it J Immunother Cancer. 2024 Oct 2;12(10):e009952
FLS-PBMC co-cultures 5 μg/mL 48 hours To investigate the effect of Pembrolizumab on MMP-3 production in FLS-PBMC co-cultures, results showed Pembrolizumab did not significantly increase MMP-3 production (P = 0.76). Arthritis Res Ther. 2022 Feb 14;24(1):43
PBMCs from healthy controls 5 μg/mL 48 hours To investigate the effect of Pembrolizumab on MCP-1 production in PBMCs from healthy controls, results showed Pembrolizumab did not significantly increase MCP-1 production (P = 0.43). Arthritis Res Ther. 2022 Feb 14;24(1):43
Peripheral blood mononuclear cells (PBMCs) 5 μg/mL 48 hours To investigate the effect of Pembrolizumab on MCP-1 production in PBMCs, results showed Pembrolizumab did not significantly increase MCP-1 production (P = 0.77). Arthritis Res Ther. 2022 Feb 14;24(1):43
Synovial fluid mononuclear cells (SFMCs) 5 μg/mL 48 hours To investigate the effect of Pembrolizumab on MCP-1 production in SFMCs, results showed Pembrolizumab significantly increased MCP-1 production (P = 0.0031). Arthritis Res Ther. 2022 Feb 14;24(1):43

Pembrolizumab/帕博利珠单抗 动物实验

Species
Animal Model
Administration Dosage Frequency Description References
Human Pdcd1 transgenic mice B16F10-R tumor model Intravenous injection 10 mg/kg Twice a week To investigate the role of COX2 in acquired resistance to anti-PD-1 treatment Cancers (Basel). 2022 Aug 26;14(17):4134
C57BL6/J male mice Nontumor-bearing mice Intraperitoneal 2 mg/kg Weekly for 2 and 5 weeks Establish a model of Pembrolizumab-induced cardiotoxicity, finding that Pembrolizumab caused coronary endothelial and diastolic dysfunction at 2 weeks and systolic dysfunction at 5 weeks Basic Res Cardiol. 2025 Feb;120(1):263-286

Pembrolizumab/帕博利珠单抗 技术信息

CAS号1374853-91-4
分子量 146.6 kDa
SMILES Code NONE
MDL No. N/A
别名 MK-3475; Lambrolizumab
运输蓝冰
存储条件

In solvent -20°C:3-6个月-80°C:24个月

AmBeed 相关网站 AmBeed.cn AmBeed.com
AmBeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
  • 客户支持
    技术支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    积分商城
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    AmBeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务,不为任何个人或者非科研性质用途提供服务。